SLCTR/2007/008Completed未知
Clinical Randomization of an Antifibrinolytic agent in Significant Haemorrhage
ondon School of Hygiene and Tropical Medicine0 sitesStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •All patients whose age is 16 yrs old or above with significant haemorrhage following trauma.( systolic blood pressure 90 mm hg and / or heart rate is more than 110/ min.) within 8 hours of injury
Exclusion Criteria
- •Patient who requires tranexamic acid as a treatment or its use is contraindicated
Investigators
Similar Trials
Completed
Not Applicable
Randomised controlled trial of fibrinolytic aided pleural drainage during chemical pleurodesis for malignant pleural effusioMalignant pleural effusionCancerISRCTN31343854Department of Health40
Active, not recruiting
Phase 1
se of fibrinogen in the treatment of bleeding in thrombopenic patients after intensive chemotherapy refractory to platelet transfusio- Major patient- Patient with malignant hemopathy requiring intensive chemotherapy, autologous or allogeneic hematopoietic stem cell transplantation- Grade = 1 hemorrhagic symptom according to WHO - WHO classification- Body weight between 38 and 78 kg- Patient presenting with a platelet refractory state defined according to the Corrected Count Increment (CCI)- Patient affiliated to a social security schemeMedDRA version: 21.1Level: LLTClassification code 10066481Term: Hematological malignancySystem Organ Class: 100000004864EUCTR2021-000990-10-FRInstitut de Cancérologie Lucien Neuwirth10
Active, not recruiting
Not Applicable
REPLACE (Randomized evaluation of fibrinogen versus placeboin complex cardiovascular surgery): a prospective, multinational,multicenter, randomized, double-blind, placebo-controlled, phaseIII study for the use of Fibrinogen Concentrate (Human) (FCH) incomplex cardiovascular surgeryAcute bleeding while undergoing aortic replacement surgeryMedDRA version: 14.1Level: LLTClassification code 10049052Term: Aortic surgery NOSSystem Organ Class: 100000004865EUCTR2011-002685-20-PLCSL Behring GmbH152
Active, not recruiting
Not Applicable
REPLACE (Randomized evaluation of fibrinogen versus placeboin complex cardiovascular surgery): a prospective, multinational,multicenter, randomized, double-blind, placebo-controlled, phaseIII study for the use of Fibrinogen Concentrate (Human) (FCH) incomplex cardiovascular surgeryAcute bleeding while undergoing aortic replacement surgeryMedDRA version: 14.1Level: LLTClassification code 10049052Term: Aortic surgery NOSSystem Organ Class: 100000004865EUCTR2011-002685-20-FICSL Behring GmbH152
Active, not recruiting
Not Applicable
REPLACE (Randomized evaluation of fibrinogen versus placeboin complex cardiovascular surgery): a prospective, multinational,multicenter, randomized, double-blind, placebo-controlled, phaseIII study for the use of Fibrinogen Concentrate (Human) (FCH) incomplex cardiovascular surgeryAcute bleeding while undergoing aortic replacement surgeryMedDRA version: 16.1Level: LLTClassification code 10049052Term: Aortic surgery NOSSystem Organ Class: 100000004865EUCTR2011-002685-20-CZCSL Behring GmbH152